Ponatinib-d8

Ponatinib-d8 (AP24534-d8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

Product Specifications

CAS Number

[1562993-37-6]

Product Name Alternative

AP24534-d8

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H319

Target

Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.91

Solubility

1 M HCl : 50mg/mL (ultrasonic; adjust pH to 1 with HCl) |10 mM in DMSO|DMSO : 25mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(CN2C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C2([2H])[2H])C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C5C=CC=NN54)=C3

Molecular Formula

C29H19D8F3N6O

Molecular Weight

540.61

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16 (5), 401-412.